BCR and chronic myelogenous leukemia, BCR-ABL1 positive: As a benchmark for targeted therapy, CML cells dependent on BCR-Abl for proliferation are inhibited by Abl inhibitor imatinib with IC50 values in the range of 80–600 nM (38).